[Form 4] IDEXX LABORATORIES INC /DE Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IDEXX Laboratories Executive Vice President Michael Perkins Johnson reported equity award activity and related share settlements. He received stock options for 3,207 shares (non-qualified) and 162 shares (incentive) on February 12, 2026, along with 770 restricted stock units (RSUs), all at a grant price of $0.00 per share.
On February 14, 2026, 176, 179 and 218 RSUs were exercised into the same number of common shares at $0.00 per share. In a separate tax-withholding disposition, 178 common shares were delivered at $629.35 per share to cover tax obligations, leaving him with 2,794.687 directly owned common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
573 shares exercised/converted
Mixed
10 txns
Insider
Johnson Michael Perkins
Role
Executive Vice President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 176 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 179 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 218 | $0.00 | -- |
| Exercise | Common Stock | 176 | $0.00 | -- |
| Exercise | Common Stock | 179 | $0.00 | -- |
| Exercise | Common Stock | 218 | $0.00 | -- |
| Tax Withholding | Common Stock | 178 | $629.35 | $112K |
| Grant/Award | Non-Qualified Stock Option (right-to-buy) | 3,207 | $0.00 | -- |
| Grant/Award | Incentive Stock Option (right-to-buy) | 162 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 770 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Unit — 176 shares (Direct);
Common Stock — 2,575.687 shares (Direct);
Non-Qualified Stock Option (right-to-buy) — 3,207 shares (Direct);
Incentive Stock Option (right-to-buy) — 162 shares (Direct)
Footnotes (1)
- Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
